<SEC-DOCUMENT>0001387131-12-002460.txt : 20120807
<SEC-HEADER>0001387131-12-002460.hdr.sgml : 20120807
<ACCEPTANCE-DATETIME>20120807140550
ACCESSION NUMBER:		0001387131-12-002460
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120802
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120807
DATE AS OF CHANGE:		20120807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-16731
		FILM NUMBER:		121012544

	BUSINESS ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		516-961-1911

	MAIL ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_080212.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
    <title>txmd-8k_080212.htm</title>
    <!--Licensed to: 631@quality-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">August 2, 2012</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">THERAPEUTICSMD, INC.</font></font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Nevada</font></font></div>
</td>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">000-16731</font></font></div>
</td>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">87-0233535</font></font></div>
</td>
</tr><tr>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">951 Broken Sound Parkway NW, Suite 320, Boca Raton, FL&#160;&#160;33487</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices and Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">(561) 961-1911</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">N/A</font></font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former Name and Address of Registrant)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</font><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TABLE OF CONTENTS </font></font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" width="96%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">SECTION 7 &#8211; REGULATION FD</font></font></font></td>
<td width="4%" style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Page</font></font></font></td>
</tr><tr>
<td colspan="2" width="96%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="11%">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160; 7.01</font></div>
</td>
<td width="85%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Regulation FD Disclosure&#160;&#160;</font></td>
<td width="4%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></td>
</tr><tr>
<td colspan="2" width="96%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">SECTION 9 &#8211; FINANCIAL STATEMENTS AND EXHIBITS</font></font></font></font></div>
</td>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="96%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="11%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160; 9.01</font></td>
<td width="85%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(d) Exhibits&#160;&#160;</font></td>
<td width="4%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">SECTION 7 &#8211; REGULATION FD</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 7.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;REGULATION FD DISCLOSURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 42pt"></font>On July 10, 2012, TherapeuticsMD&#8482;, Inc., parent company of vitaMedMD<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, LLC ("vitaMedMD") ("TherapeuticsMD" or the "Company"), previously filed three Investigational New Drug applications ("INDs") with the U.S. Food and Drug Administration ("FDA").&#160;&#160;On August 2, 2012, one of the INDs was approved by the FDA.&#160;&#160;The Company intends to initiate Phase III clinical trials in the field of hormone therapy for menopausal women before the end of the year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 42pt"></font>The information in this Item 7.01 of this Form 8-K (the "Report") is being furnished and shall be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Report also shall not be deemed to be incorporated by reference into any filing under the Act except to the extent that we specifically incorporate it by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">SECTION 9 &#8211; FINANCIAL STATEMENTS AND EXHIBITS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND EXHIBITS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1pt solid; BORDER-TOP: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exh. No.</font></div>
</td>
<td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1px solid; BORDER-TOP: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date</font></div>
</td>
<td valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1px solid; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Document</font></div>
</td>
</tr><tr>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1px solid; BORDER-RIGHT: black 1px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex-99_0.htm">99.0</a></font></div>
</td>
<td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex-99_0.htm">August 7, 2012</a></font></div>
</td>
<td valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1px solid; BORDER-RIGHT: black 1px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex-99_0.htm">Press Release regarding acceptance of IND by FDA*</a></font></div>
</td>
</tr><tr>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="23%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="65%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1px solid; BORDER-RIGHT: black 1px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>*&#160;&#160;&#160;Filed herewith.</font><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><br>
&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: <font style="DISPLAY: inline; TEXT-DECORATION: underline">August 7, 2012</font>&#160;&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">THERAPEUTICSMD, INC.</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="39%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/Robert G. Finizio</font></div>
</td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert G. Finizio, Chief Executive Officer</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.0
<SEQUENCE>2
<FILENAME>ex-99_0.htm
<DESCRIPTION>PRESS RELEASE REGARDING ACCEPTANCE OF IND BY FDA
<TEXT>
<html>
<head>
    <title>ex-99_0.htm</title>
    <!--Licensed to: 631@quality-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right">Exhibit 99.0</div>

<div><a href="txmd-8k_080212.htm">TherapeuticsMD&#8482;, Inc., 8-K<br>
</a></div>

<div align="left">
<div>&#160;</div>

<div style="TEXT-ALIGN: center"><img src="logo.jpg" alt=""></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FOR IMMEDIATE RELEASE&#160;&#160;</font></td>
<td width="50%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SYMBOL: TXMD&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">August 7, 2012&#160;&#160;</font></td>
<td width="50%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TRADED: OTCQB&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">THERAPEUTICSMD, INC. HAS IND FILING ACCEPTED BY FDA</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FOR IMMEDIATE RELEASE &#8211; August 7, 2012 &#8211; Boca Raton, FL &#8211; TherapeuticsMD&#8482;, Inc. [OTCQB: TXMD], parent company of vitaMedMD<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, LLC ("vitaMedMD"), a specialty pharmaceutical company ("TherapeuticsMD" or the "Company"), announced today the U.S. Food and Drug Administration ("FDA") accepted the Company&#8217;s Investigational New Drug application ("IND") and now the Company can proceed with Phase III clinical trials for its product TX12002HR for hormone therapy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Robert Finizio, the Company's Chief Executive Officer, stated, "Now that our submitted IND has been accepted we are anxious to move to the clinical stage of development for our new product TX12002HR.&#160;&#160;We anticipate that these clinical trials will begin before the end of the year."</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">About TherapeuticsMD</font></font></div>

<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TherapeuticsMD&#160;is a specialty pharmaceutical company focused on creating safe and effective therapies exclusively for women. The Company&#8217;s branded OTC and pharmaceutical products are designed to improve the health and well-being of women from pregnancy through menopause.&#160;vitaMedMD provides dietary supplements and healthcare products focused on improving women&#8217;s health, wellness, and quality of life. Questions may be directed to Daniel A. Cartwright, the Company's Chief Financial Officer, at (561) 961-1911. More information on TherapeuticsMD is available on its website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.therapeuticsmd.com</font>. More information on vitaMedMD and its products are available at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.vitamedmdrx.com</font> and <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.vitamedmd.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of TherapeuticsMD, Inc. Certain statements in this release and other written or oral statements made by or on behalf of the Company are &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management&#8217;s expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward-looking statements are subject to a number of risks and uncertainties including FDA and market acceptance of the Company&#8217;s services and projects and the Company&#8217;s continued access to capital and other risks and uncertainties identified in the Company&#8217;s Form 10-K and other filings with the Securities and Exchange Commission.. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"># # #</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"\!
M5@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[V]9UG3]`TG4=<U6;[-IFDV%YJ>H7)4O\`9[&PMY;NZG*)EW$5
MO#)(516=@N$5CQ7Y/R?\%V/^"5:.R/\`M8>&%=&*.K>$_B""KJ2&!SX2.2".
MH)!Z@D<U^LNNZ#IGB/1M5T#5X&N-+UK3KW2M0@2::!IK+4+:6SNHEF@>.:%G
M@GD598G22-B'C=752/Q6N?\`@W6_X),S2R7$G[/7B9Y9I6DD)^./QN.YY&+N
M3_Q7XP"2>%X&<``#CU\JCD#]K_;<LTIQ@DL,LKC0D^16<E5=:K2MMHH\WFSY
MW.GQ0GAUP]#)6N7_`&N6:U,9%NI>*C[*.$@V^K;G425[<K>IZ#_P_:_X)4_]
M'9>%_P#PE/B!_P#,C6WX:_X+<?\`!,+QAXBT+PEX<_:D\-ZIX@\4:QIGA[0]
M-B\+^/(Y=0U?6;V#3M-LHY)O"T,*/=7EQ#`CRRI&K.&=E4$C^33]GW_@GE^R
MAX[_`."[?QF_8C\3_#S4+_\`9P\(:C\3;?0/!*>-O&MG?6<7ASP?I.K:0K^+
M;/7H/%MU]FO[N>9C=:U,9PPBG,D2J@_J)\)_\&_O_!+'P)XK\,>-O#/P!\16
M/B+PAX@T?Q1H-Z_QI^,]Y'::SH.HV^J:7<R6MWX[FM;J*"]M8))+:ZAFMKA5
M:&>*2)W5OJLYR;@W*'AZ53$<1U*^,RZEC\,DL+*ER8B*=&%=NO&2=U^]45)*
M+?+*3/BLCS[CW/%B:M&APO"A@LRJ9;B>>69JK*="HH5IT(N=2G*+C=T_:N-W
M92@E<]*^.?\`P5B^`GP"_;=^%?[!_BWP5\4]5^*7Q<'@'^P?$6@Z5X5F\"V#
M?$76=3T31O[6O;SQ;IVO0&UNM*GEU$6^A792UEMY8!=2.T,?ZN+T'T'KZ>_/
MY\U_$S_P4^GL]+_X.-OV+[V[FM[/3].MOV8+V]O;J9+>UL[.W\?>-9Y+BXGE
M9(888(T>2665E2.&-F9@B<?LK\6?^#B'_@F=\)O&UWX%?XL>*/B%?:5?2:;K
M6M?#3P%K/B'PIIEU`[03$>(;P:19:U;I<;$%]X6;7].<.I2]8>8T7FXWABM/
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MWT[7-2MF<"2WO=)T&^L[N-HY+26>.6/?^L?[-O[5WP#_`&M_`"?$W]GSXH>&
MOB;X.:<6D^HZ)-/#>Z7?>3%.^F>(-$U.UT[6O#^JQPS0S2:;K&G6=VL4\4OE
MF*6-F[,5E&:X*DJV,R[%X:D[+VE:C*$$Y)-)SE:*;3NDW?R//P/$.29G6^KX
M#,\)BJ[4I*E2JJ4I1C+EE*/1I2TT=_*VI]'45\"?M!?\%(_V4_V8_CO\+OV;
M_C%\1M1\,_%SXRR>&E^'WAJR\">-O$L&L_\`"7>)W\&:#YNN^'_#FI:)I:W.
MOHT4S:IJ%JMM%^_FDCME:0>+_M1?\%H/V!OV1O'$OPM^*7QH.H_$NVNH;'5/
M!?P]\+:YX]U3P]<O.D#Q>([_`$*RD\.Z)?1,X,VD:GK-IK,0(9M+`$@BSH9;
MF6)=)8?+\9656BZ\)4Z$Y1=*-^::=M8PM[S5TKJS=]-,1GF481U8XK,<)AY4
M:WL*D:M>FI*J^7EA92;O/F]U-*]G>UC]8Z*^)_VHO^"A'[(O[&-M:3?M'_'/
MPC\/+W4K!=4TOPU<+J6O>,]2TUI[BU2_T_P7X3T[7O%MY92W5G=VL=Y%HAM6
MNK2Z@$P-M.T/YVZ!_P`'(7_!+C7/$$6@S_%OQOX>MYY$AA\3:_\`"+Q_#X>,
MCOM4S-IFBZMJ]I;,V$:\O-)M[2T!\V]GAC!<;8?)<XQ=%XC"Y9CJ]%?\O*>'
MG*+:=I*+2]YP^TE=HQQ/$N08.NL-BLWP-"L[>Y4KQ32DDXMVO9237+W['[U4
M5Y7\,?BYX!^,W@O0?B/\+/&WA[Q[X#\4V4>H>'?%'A;4+75]*U2UD1LF&XMO
M,"SQ2*\4]O-Y4]O<126US%%<*\*?&?P]_P""JW[$WQ+^(_QO^%V@_&FUT_Q1
M^SCH_B77OC+)XM\->)O!/AKP;I/@_P`46_@W7[N7Q3XJT73-!U-;7Q)=VVG1
MMI.IWJ7AD\ZR%Q%@MR4\+B:WMU2P]><L-)0Q$%1JJI0FY*$85*<HJ<).3LKQ
MLWL[G;5S/+Z$*%6KC<-3I8I-X6K*K!0Q$5%3E*C)OWXQB[RV:['Z045^!^O?
M\'(__!+K1/&3>%8?BI\0->TV.[-G-XXT+X1^,KCPE"ZM$KSJ][8:=XCOK)#(
MY%SI?AN_CN%MY);0SQ-`T_ZX_L__`+3'P4_:B\!V'Q/^`OQ+\.?$_P`":@[6
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M[7G[/W[7?@1?B/\`L[_%;PW\3O"OVC['=7.C_:+35-%O3&DR6'B+P]JT%AKV
M@Z@86\Y;/6-.TZ>6(&YMXIK8%AY5\1_^"C7[+'PG_:F\`?L:>./B)J6E?M`?
M$Q?#C^#_``A%X$\9ZA8ZDGBVXU"ST`S>*=/T"Z\,V'VVZTN\C9;S5('MRBM.
M%1UK%83%RQ&(PL<-7>*PL'4Q&']FU6I4E\524'9J"U3?22:=F=$LSR^%&CB9
M8R@L/B*D:-"O[1.E5K3:2I0DKWFKW:LM-4V?>E%4WDF$)*D>9A1\HSM+$`D?
M(=VP$L!L^;&"!G(^#=4_X*2_LIZ)^V!;?L'ZK\1-1@_:;OY]-MK3P,/`?C=]
M/DDU?P;'X^T__BL(O#\G@]1/X6E74"C:X)(WVVTIBG;RQ%&A7Q"FZ-&=5TH>
MTJ*"YG"G%KGG*VT873D_-6NVC7$XS"X-1>)KTZ,:E6G0IRJ2Y8U*M7^'3@];
MRELE;H^Q]7_$/XM_"GX2V.GZG\4?B+X(^'.G:M>MINE:AXY\6Z!X4L=1OXX3
M<R65E=Z_J&GVUU=I;AIFMH)9)_+1Y!&41F'?Z3J6GZQI>GZMI-Y:ZCI>J6=O
MJ&FZC8W,-Y97]A>1+<6=[9W=L\MO<VMW;R1W%O<02/%-#(DD;LK`G^(O_@YM
M_;._9_\`C%IOP_\`V7_A]XPN]8^-/P!^-.O3?%+PS)X4\4Z;::##J7@-8;"6
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M]/OM22[ATW,EHBP:C:B!Y%(N)9/)CS)A3]<?#KQSX?\`B?X$\%?$CPK-<7/A
M?Q[X5\/^,O#<UW;/9W4FB>)=)M-9TN6XM)"9+6>2QO('EMW)>&0M&WS*:_)O
M_@KM>?\`!,>V\"_!C5?^"G%I>W_A"/Q9XFM/A4VGVGQ:NY8?$=YI&F7>OK)%
M\)(9;](VTZPLSOUA?LS)!BSWW;^1/^G7PA'@33/@W\+H?A8!:_#:S^'G@Z+X
M?Q2M?*;?P-#X?TQ/#2RKK3_VH@BT,62RG4R=10`FZ!NMX/CXFAAHY5E^)IX7
M,(8FI6Q#K5ZB<<)64*DJ*AAXJ\ZDJ48_O8N*5XOEOU]K"XO%5<]S/!U<7EU3
M"T*.'=#"T[RQN';A"K*>*<E&G"G5E)RHRC.7NRCS*-FE[!17XO?M"_\`!>W_
M`()N_LY>*M3\#:]\:K[XA^+=$N19:SI'PB\'ZSXZ@TNY$ACDAN_%%O#I_@J:
M[BD!CFT_3_$=UJ%NT<BSVBN4%>W_`+('_!6S]AO]MK7/^$0^"7QJL;CX@+')
M,?AUXUT/6?`7C*XBC\]F.D:?XDLK*R\2F**WFFNE\*ZGKIL(HW^WFVECE1:G
MDF<T\.L54RG'T\.X*K[66'FHJC)755NSM!J[3ZKU1I3XDR"MBG@J>;X">)4W
M2=-8B%_:II.DG>SJ)NUKVOU/TRHKP_XX?M`_"C]G#X>:[\5OC9\0/#_PX^'_
M`(=\L:IXD\17"PVL<MQA;6RM+>%9K[4M2NY/DLM-TRVO]1O')6"REVL5_(C2
M?^#C[_@EO?\`B8Z#>?&#QQH^G"9X$\7:G\'?B)%X8E(D""8"VT&[\200;B?W
MU]X=LU5%,TR1P%9VRP>5YGF%*=?`Y?B\51IM)U:-)RB]N:VSO"]I)I-.RZHU
MQV>Y1E=6%',<PPN"JSC&2IUZU.,K2:46U&4K*5[Q>S5WT=OWCE<1QNY&0JDX
MXY]AD@9^IQ7RSX;_`&P?V<_%7QFUG]GW0OB7I-W\6M"O-8L-0\'26NJ6E['?
M:"L<NKV4%Q>6,&GWMU8PR?:9K:SNYYA:QS70C,,4LB^@_!WX]?"']HGP38?$
M3X)?$GPG\3O!&HR>7;^(?!^K6FK6)F4KYEE=F%C<:=?P[D:XT^^AM;V+<!)&
MA^6OX[?V@?#'Q=G_`&[_`-L#XI_!66]A\6?L_P#C_P`0?%^Y?3Y)7O[;2-,\
M8:)H-[<K$KJ+FRM/[;AN-9LW\R*X\/6VL++!)$DD;^ID>34LPJX^EC)U,)B,
M-0BZ%*JO9N6)G/DA3:G'XKM-[*UK/FT/QGQL\6,R\-L)P?F&2992SVAGF>3P
M>/I4E*O6GE6'PT<7C,1@(TDXU*N'HJI5E&I.FN6$G?1G]O*$%%(P054C!!&"
M`1@C@CT(X-03.J$LW``YX&&`!.&.00!V]_J*^0?V+OVK_#7[6_P.\,_%+0Y[
M:RU-HFT7QGX?$BM-X;\7:9#"-4T^8RXD-M,7CU'3)VS]ITF^L;DDM)*L7!_\
M%"_VQ=+_`&0/@5K/BR.:TOOB#XM@G\,_##P](T;->^)KJ!P^KW,*YDDTCPW;
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MP]^)?@#_`(*<?LP2?&`WS^//B7HGC/XN:R-7E>?6?^*X^%/Q5U"WDUV25I&D
MUNZ6-[_4-[F:TN;ZYT]X[>2&X6;[F_X+#^'M&\2_MD_L*>&==T^#5-#\0:C;
M:+K.G709H=0TS5?B+X:LM0LYV5EE\JZM'DMY=DB'RY90I&]L_4RX=P<,WP6!
MGBJTL/6RZIC*\Z:BZBJ4X-RIQNU%.,H.*?,UL[L_G'!>/O&.:>%_$_&N'R#+
M,NSG*^.LMX4R[+<RI55!83,J^7T:-3,?9N4X5%]?I3J0IN5HJ7*Y-1O^FME_
MP5/_`&"]0NH[1/V@O#4(FVB.:^TOQ+:6REB54SSW.B106\9&'::XDC@1#YCR
MJN<?9?@7XJ_#KXH:)!K_`,-_&OA7QUH,Y"Q:QX4US2]>TXOC<4:[TNZNH%D4
M`[XBXDC;*NJ,"*^.[O\`X);_`+!NIZ9-8R?LX^#;;[6DBO<Z?/KMA>Q&<,KR
MV][;:JLUK*H.4DA9'!``(48'Y)_M.?L6_%7_`()KZO+^UA^Q;XQ\3P_#OP]?
MVW_"Q/ASK<]WJMI8:%/?+:1R:GB6$>*/")GE2*87\$NM>'FN3J<.J2AI[V'@
MIX+),;-8?`8C'4,6YJG16-E!T*E25E9RC*3B[;>Z]>A]OC.,O&7@;#PXAXPX
M>X2XAX7H4XXG.L3PA+,X9SDV"E3=6IC%@\;",<9@\-&+E55&I[6"3DX..W]!
M'Q-^.OP]^$5_X>M/&\OB6*?Q/=&ST-=!\#>,_%RW%_\`,$L0WA30M92/4IE2
M>6UTZ0I>WEO:7MS:P36]C=RPY#_M.?`V."[N9OB!HT"V7Q3TWX+30SM-%>I\
M4-8U"STO3O!HL'C%Z^JWES>VTL2Q6[VYL&;4FG%A&UR/'?@Q\0_#'[<7P3^!
M/QK\.7IT&'3/%VD>,M6T40KJ%QIWB'PWIVM:+K?A&YG9K4JD=[JCR0WRQ.9[
M,6]R+5$N#Y>3?_L'?#R_UJ'QE/=W`\<VWQ4C^(T.O_9KI+66&#XV1?&&#3[C
M0QJ(T^?7[2R^W^![#QC)LU6S\.ZOJ=G;PKI][/I8\J-+#4)U:&,4J6(I3G3E
M""3;G&5FI<SC;FWNM[WLV?H,,WXFS:G@LZX666YOP_F^&PN88#%5)NA4^I8O
M`4W"7M*:JRQ%52G9PG&BXI.,G>-G]]V[)-&LL7".-PSC/)/<%@>0>02IZ@D'
M-%1VB>3;Q1KPJKA?O'Y<DKG>`<@$`\#!Z`#`!7GI*%XJS2;M=:VO=)ZO;;?N
MC]#@JG)"ZC"7)!SBMHS<8N:V_FOOKT?4OTQ^@^O]#3ZAE/0`]""WT_SZ?C4M
MV3;LDNK=EVU?370T?1=Y12];H_BN_9._Y6C/VB_^PO\`&G_U7V@5_:>W(`]5
M/\S7\5_[)K`_\'1?[1I'1=8^-08^F/A[H!.?\]:_M0++A>>Q_0DU]KQS>.+R
M&^G_`!C65[Z?9U_`_-_#Q_[%Q"E\4>*LQNNJ?M=+KH_)_J?P2_\`!>GX2ZO\
M>O\`@M3\%?@AH&HIH^J_%GX;?L^_#Z#5Y6*QZ9'XM\:^-]'N]2<(6DECT^QN
M+N:2W$)%SE+4F1+B6)OZ:O`/_!$'_@FKX!^%-C\+KC]F'X=^-Q'I,=AK7CSQ
MGI?]J_$?7+V2U%O?:R/&9F@UKP]?7K>;((O"MUHEI9O(JZ?;6T:^6?P:_P""
MFY!_X.0OV)`<$!/V6#@X(S_PL7QEC(/!.5!&>00",&O[4BI*#@]5]ONDD>G0
MC/Z&NO/,SS+!9)P?0PN+Q&#A+*(5D\/4E0G.3Q<[.4Z?+.<%RNT7)Q\MV<?"
M^397F/$7'%?&X+#8N=/B&6'C]9IQK0A3GA*;GR1J*4(3;LG424U9>]H?PK?L
M3?#;6_\`@FA_P<'7'[)7P[\0ZW>?"KXFS:SX7AL]4NY'_M?P#XH^'5S\4_"B
M:Y#''#!>ZIX-UO28],@U5X_/N#97%Q#]DBU74;2X]4_X+U_&CQ7^U+^W]^S_
M`/\`!,[3_B+IGPS^$FD7_@'5/BSK^KZM#I/AR/Q%X[,>KGQ%XIGOIX+26'P%
MX`2/5/#EA?3QPRZKKUP?/CN+C3KBSZ3X[*!_P=3?`A!\J"V\'$#G`(_9Y\9*
MI]3P!GGG`[XKY%_X+E?`7X?^%O\`@LEX(\?_`+2@\4:1^S3^TU9_">Y\4>,?
M#=V=.U#2=)\,^&]`^$_BZYTS4[C3]3A^T>#CH6A:_K5G;V=_=QZ3JBI)ITES
MJ%C*?K<(J6*X@R;&8Q6QM;@QXV-6G1A6KUL;[*45B%2G.G&IB/8N56,'*+DX
M<ZYF?%8YXK!\,YYE^"C&.$P_'<,"Z4ZDU1IX'VUW1J3BW*C0E.$(2G>*@G:]
MFT?T*_#7]B/_`((<_#?X2Z9\*3I7['/C*SAT2#3=8\8^._&'PW\2?$;Q)=+9
MQPR:]?\`C>ZU;^WK36+F5#>P2Z'=:79Z=/*W]B6&E(8EC_`;X%ZGX2_X)3_\
M%LO!'PL_9Q^*EAX__90_:9U3P9X5N++2/&6F^--%L_#GQ.UNX\/:)9:K?Z5?
MW.G2:]\,?'5OY]AJMXD>OQ^$FG6X+6VO337'ZQ^&_P#@V8_X)G^+]`T?Q5X6
M^(OQR\0^'->TVSU;1-<T3XF>%-2TG5=*OX(Y[&^TR^L_!;VUY97-L\<UM/;.
MT<D+HR,00:Y?X:?\$9?^"0GPA_;`^''PR\-_M#?$2;]I?P)?Z#\8_#_PMU#X
MH^&;S4IU\):]97]A%J5E;^#85^T37%O#-+X>&H6_B&;0?-U"VM(M,47R>/A<
MTR&C#-L/4S?B//:.*R[$T\1@<=@$J2KU:;5/$.%6KB'0>'K77M8.G:,>5^ZK
M'O8G*<\JRR:O1R7AG(EA,QPTL/B\'CW2]O3]I&+H1<)QCB_:03DX7JN^O<_,
MW_@YRU;Q-X;_`."AG[,GB+P1>7=AXRT#X+>#]:\)7^GC=J%EXFTSXJ>*+[0+
MRP!5E:]MM4@L[BW5@RF:-<XX-?J[^P?_`,&ZO[,/ASX8^'/B3^VEI&O?'G]H
M3QY9V_C+QY8Z_P"*O$^E^%_"WB'7HDUB[T>U3P_JFB:WK>KZ;J%U*NN:]K>K
MWB:MJ4=R]I8Z?92F!_@__@N[96>I?\%E_P#@G'87T$=Y8WI_9\M;NTE19H+F
MVG_:+NXI8)XI`R2P31DI+&X97C=E8$$@_P!JR*$CVCC"X'_?`],?G].:Y\]S
MO,,NX5X/P&!Q%6@J^5U<15JTI^SG/#5:\J5*G&I&TN6%IN2BUS72?1/LX?X>
MP&9\7<:XW,<-0Q,L'F=&-.C-*="%54(3DW!OEYTXIWDN:)^+7_!27]FG_@E=
MXX\;?#;]HG_@HIXC\,>&F^'OAW5/!/ABQ\4^.;KPQIOC+3)-8?6QIEUX?\.R
M1^,?&4OA^ZFU![+3-+G:*`:QJ4LMC<&X+1_F#\0]:_X-?_C1X/U+X8:3J?P:
M^%VHZE8S:3X=\?\`@SP'\4/A_K^A:M-#+;V&KQ>*?^$6MK*\FM'5)43Q8UYI
M,Z1^1?6\@VQ'X4M/A;X9_P""H7_!?#]H'X1?MB>,M;M?AY\,_$7Q4\/>"_A^
M^NWNBIK>B_"'7+30/"WPWTFXM[FSNM+@UBQDU/QSK<^DS17^H16NM7-AJ-O+
MJ$]U7])WC?\`X(]?\$DM#^'>M77C/]E3X.^&/"/AS0;Z^USQ+=:CXE\-WFFZ
M-86\UU>WNJ>,+3Q+I^LK%:6\+S7%S<:F^P1"<D%$`QG/#<.PRC!XS-^)GC<5
MAJ&*H4,OQ$:>$IPK_O*:BFU*M4O_`!+IW=DELB*<L9Q&\XQV`R3A:E@<'B*V
M$KUL?1<\:YX>T)R<K.%&%K>Q=XJ-KNR=S\1_^#83XI>)/"GQU_;._9"M/&D7
MCGX6>&[2X^(/@K6-,OUOO#L^H>&/'3^`-4\5^&Y8I)8)K#QYI^JZ!JKW%NYM
M[M-(L+R$LLTQ;\O?V>OV(]8_X*`?\%?/VIOV?Y?%>N^$?A8/C'\;?'/QQO?#
ME^]E?:A\._"7Q8E,6CVBR1RVDNI:GXIUGP_;:?)JMAJ=II=S<?VZEK=MID<<
M7WG_`,&UH^'Z?\%)OVVX_A,D\'PJ3X9>/H_AC:W<]W=75K\/H_CSX<3P;;75
MS?SSW]Q/;^&_[,BFGOY9;ZX<?:;R:2YFD>O+_P#@F7^UQ\.OV5O^"W?[7%E\
M6-:L/#/@GXZ?$;XY_">+Q+JUS!8:-H'B^?XPOXB\*76K7TQ2.TL+Z;2+_0%O
MKB2*UMK[6E-S(BJIKZ[$U,53SKC;$9;2Q,\;+(LLKVKTH?675=&C>K.C&-YU
M&KS3E%WE:7Q:OXVC]6Q>2<$4<YDXX"CQ+F.%K5/:2G&%&523A"-6Z_=2;4='
M90OJHG]1Z?\`!%C_`()E#X<_\*S;]D?X52:4VFG3SXG;2)3\2&9XW4ZBWQ*:
M=O'#:D)'$Z7!UWRT95@2!+$?9*_F2^#?A_QO_P`$2?\`@M7X3_9N\.>--:UO
M]FS]HS5O!VCPV&K3,R:WX)^)U]J'AGP->:K;P&WTUO&/PX\=QOI[:I9VL*W>
ME#4(X+'2[3Q-]DL?[IX-5TUK0WJW]JUEY(N_M8N(VM1;-$LJS"X&(C`T169)
MBVV2)A*K%"&K^'?]L_Q_H?\`P44_X+_?LP_#SX"WD/BWPY\"?%GPQT'6?%^A
MM'JNBW4WP>\9:A\6?B9K=OJ4$CVAT;P_'#-X?2YBG\JZUNS,2/<V^I:-+)\=
MP=F6:9E5S?#YE7Q&-RO^Q\QJXY8FM.I1PV)IX=RIS4JC<:=:-2W+9QD]$TTK
M+[_C;+<JRV&2XK*L-A,#FL<WRV&"^HTX4ZV*PT\1%3BU2M*K3E!>^W&48WNW
M=W/6_P#@X,^.GC']H;]L[]G3_@F=X9\>Z;\.OAS?3^`O$GQ6\1:WJJZ3X;'B
MGQUJUZ-,O?%]U)<6MO+H7P]\&VJ^+X!J-T+:XO\`7IY]B:CIFER2_K'\)/V'
M/^"('PG^$MG\)EM_V.O'EN-'73-<\:_$;Q=\,/%7Q#\278C<-K5[XOO=174M
M/U(73O?V8T,Z99Z-=,6T.TTY(X%@_`3_`(+\_`CP7X0_X*R?!WXG?'^V\5P?
MLS?'WP[\,6\8^)?"LKV.J:78>%+J;P5X_M-(O[FUU")=:\-Z/9^&_%3VLELT
M,MIJ=G%%#([7#VGZS^%O^#:+_@F/XX\/Z+XL\)_$;XZ>(_"WB'3;75-`\0:+
M\4/!^HZ+K&GW<:RP7^G:E:^#)H;RWN5D4Q2QR^6P4^6N,,>_&5,JP_#G#47F
MN:95AZN%^LU)Y92@H8G,)5?WGUBNY1;JTTHJ-%R7+&3M%7:?@82EG..XGXHG
M#),HSG%4<8J%.GG>-=&>&P<8?N9X3#SP]=2IR7,Y8A0B^9*TWT_)OP)J'@7_
M`(),?\%K?ACX;_9>^*>F^/OV4_VE-8\(^'=5T70/&FG>+](M/#WQ-U[4/"=O
MX5U;4M*OKB&ZU#X9^.KRVUSPK=:B\FK)HK117EW=?:]6DU#Z@_X*!2*?^#EO
M]AXKG:]K^SJP(.>OB?QRN#UY^4GC@J5.<D"OHOPE_P`$6/\`@D'\'_VM?AG\
M*-/_`&@OB''^T;H.H:+\6O!?PRU'XL>$;G6[MO!.M:;K-O%?6(\)0Q;KZ:P6
MZCT*ZD@U>]TFUU;4=-@-EID]\GQW_P`%:_&VD?`'_@X!_8Q^,WQ'DDT3X>:5
MH7[//B"_\0W2-#I]KX<L?B3\0-#U[4GNVC*HFAWD,MY?;)E%M:-$9_)M;J(R
M=]'&X#-,RISP2Q5?'0X0S/`XC$5\,\/B<=6C&I6HU'3A%+$5'2:3DHR<VN:[
ML<E?"9IE>33>81P=+"2XRR^KA\+A,9'&4L')RI*M%5;N4*;NXQC+E6J]R+>G
M]MJ@LNX''*,0>>#@XS],#/>OXJ_BF0W_``=@>$^,G^W/AUUYX_X9`T]/IRS;
MB?;FO[.8O$&B7.BP:Y8ZQIMUHMQ8P:G;ZO;7UM-ID^G2PI<P7\5_$[VLMA+`
MRS+=QR-"\+;HY#D&OX8_#WQP\"_M"_\`!T'X3^)?PSU>V\1>#&^)Z^#M-\0:
M?<P7NE:Y-\._V>+[P+JNIZ/?6Q-O?:3/K/AZ]-A>V\LUO=0*DT$\L+(U?*\%
M4*DI\2U8+W,/PWF<*[=G&$YJD_9RYKJ%1R6FTHVLK:'VGB#B,.UPM!U/>K<3
MY34A&-G[14HMJ22TG"+DU)*\;VO?0]M_X.AOV6/@%\*_!OPA^/\`X&^&NA^'
MOB_\8OC3X@A^)7C>REU)]3\70V?@>6>U34H;F^GTZ+R9[6SF4Z?96;$P%9"X
M*[?V?_9&_P""0W_!.6]^!G[-'Q9NOV6?`5Q\1;KX5?![X@W'BJ:^\6M?R^,Y
M_"?AWQ')K[0GQ']C-T=;8W_E?9_LWF?NS"8ODK\Y?^#L5'E_9I_96E5':*+X
MX^)H9I-K>5%*_@&_*1R2$!$9_)E*!B-XBD*Y"/C^B[]C'6=(OOV0/V7;VSU*
MQNK*7]GGX-M'=6]S%+;,L?P\\.0RD3(QB_=2JT4OS?NY5:-]KHRCKS/,\QCP
M-PK;,L="=3&YY1J\N*JQ=2C2K451I32E[U*FFXTX/W8JZBDCFRK*<JJ>('%-
M*MEV"DJ6`R7$TXU,/2;AB)PYZE:'-&ZG.=I5)K6<E>3;/YOO^#LF`P?L]?LD
MAB&/_"X_'`W#/('@6/));)W,2Q(R0,@*``08_P#@M1^V]X]_9U_X)N_L<_L^
M?"/6;_0/'?[3'PD\$V&OZYH]S/:ZOIOPU\-^`?"B:QINF7%FZ7=O?>+]8UC3
M=$,D*R/+HMKXDL=@%X9&M_\`!VA(DG[/?[))1@V/C)XY)X(QGP+'C@@=<'\J
M^3?^"_WP>\91_LM_\$QOVH?#-B][HGPY^%/A#P#XDNQ;_:[/0=4UCPGX,\5>
M#;S4X&$L4=IJ=YHNM6+7<R1VRS00V=T7>_L`GT'#M'#XO`<!T,7RSC_:>?2I
MPJ6<:N(C3JU</3J2?25;E2B]'IHTSYOB>O5H9QXAU,$^2:RG(85JE"7).AAZ
MD\/'$U(1IZZ4I2<I)+E2T>FG[`?\$[O^""_[('P%^!_A.\_:#^#G@?XZ?'?Q
M1HEEJGQ!U+XFZ'9>,O#GA[4]2MH+BX\*^$_#6KK=^'K.TT(;-.EUW['=ZUK%
MW%?WC:LNGWMM86='XX?\&[?[)OC7]H+X/_'/X&:IX@_9B@\'>.+'Q)\0?!OP
MINKC3-*\0Z?I1_M'3SX#D>62;X9ZZ=8LM.@NKG0,Z8='ENUTW2M,U:WL-4A_
M6C]C?]K3X1_MC?`#P-\=?A3K^FWND>)](M+C6]#@U""[U?P7XDB@2/7?"?B.
MUC;[3I^K:+J2W%HT5U!;_:K5(-2M8S8W=M(UGX\?MG?LR?LT>(?AIX4^.'QF
M\&?#CQ!\6_$B>&?`VG:_J207.J7SQ._VV[V;X]$T!)?(M9?$.LFQT"VO[NPL
M;K4H9[Z!)/@JF=\41S7%QEC<P>-MB*-3!*52HH8>,I)Q^JVDE3C!:/V?+!7:
M:NV?H.%X>X0EDV!G/"9:L(EAJM/'N=.E.IB>6$N:6,4U.5253XHNHW)NTHW1
M_+U_P=/)XTT^_P#V);/Q!#XCOOV<[35O%TGBRVT:YE$MYXRBGT%6AFN;TS6:
MZ[)X,.K+X=NM1<W1#:ZUM))&NL>9]U_LZ_"S_@WW_;6^%OA[X>?"7X>_LP2W
M=UI4$$7A*\AL/`7[0NF7DL<,4@O=4O;K2OB7?ZRL[6HGUBVUO6;;4;F)XFU#
M5/)P?U[_`&B/$?[&_CVY\-_LR?M,:U\'/$%W\;M+OM1\(_"KXF7NARW'C>WT
M<V:R7FAZ?JTL3MJ5I)=VS:7<61MM2:X$ITB1Y+2Y,/X-_MA_\&TO[(6K>$O%
M_P`0/V9/'WB_]G#Q9H>D:QXDTK1]9\1S>-OA?#<:38W.JI;3ZAXHN9_%WAVQ
MN3;[3KB^)]2705D>\BTB_BA.G3^WE>;9=B<KRS*LQQF;Y#BL-5QCP&9X"'+A
M\34Q6(A[F,IRY)S2G>*J4N9K9/ENEX&<9'C:&<9QG678').)<)B:&%AC<MQS
MB\3@:6$P[O5P]2;DD^5:QBTI/[+E:W[>_L+_`+`?P&_X)_\`POU?X8_`2TUC
M^QO$GB_5?&NMZSXKOK;5_%&JZAJ$LD=C97VJV5EI<5U8>'=*^SZ'HD36B20V
M,,DMRUS?7VHW%U^8'[#NGV>K?\%;?V_M.OK:&ZM-0T'X@VEU;W$:S6\]E=?$
MCP.+JUFAD#)+%<*T:RHX972,QGY)&%>7?\&T?[8'QU_:!^"WQY^#WQG\3ZKX
M\M/V<?$WP_TGP%XQUR\EU359?#OC>S\9,_A:YURX9K[7+7PO<>"Q-IMWJ-Q?
M:A'8>(+>R69-)LM/M;'US]@PA?\`@KU^WB6.`-)\=`Y]3\2/`0'UY('&:PE@
M<9E^)XMPN/KO$8NA@\-.5?FYWSRJPE"I"=W:7LW"5XM6;[GYSQKBL%FF=?1\
MJ8##>PP&)XYS*FL''F<)..18ZG5H3@VW.$X.NI4VG&I3C=IJ":\EUA-1_P""
M0?[<!U>"&];]CS]H>?[-/%;6]U<6GA*Y%SYK11A&#/JO@>Z1KBSC0S7&H>#]
M6OH[:*\U725C@W_V??#>O_\`!4[]M#6/VEOB#9W47[,?P%U:WTSX6>$]6MIQ
M9^(-3@N8+^QMI+61Y+6:62\L;/Q;XP1@1ONO#VB*L]F@:']N/VL_V7O!7[6?
MP7\3?"+QA&UDFIK'J/AOQ+;6J7>H>$_$]D)#I/B'3X'FMQ-+9O*Z3VHN+<7U
MC/>6+3VXN3.G7?`'X%^"OV=_A-X.^$G@;3S9:%X.TM+-9953[9J]](3<:IK>
MHNAV27^KZE+=ZC<N%10]SY:1PQQI#'Q3SVC+"1KN'+G,L-'!5<5'5RH<KM4<
MEI[6S455^-MV;2WPPO@CG5+B]9)4S&@_!7"YF^,,!PY&565>KGM5\T<EJTHR
MM#)\+B(QQ5/#M^Q<Y1BJ;NT?B;\3H([?_@O5\!(XE6-%^'<XVKD(?+^#?Q9B
M!`8EATPJL7"`%E(>>4M4_P""M;?\9S_\$_<C@>)=%(Y^\/\`A9WACGCIG!J]
M\5BB_P#!>SX#L7`5?AY/U(&0WPB^+B\9Y)RN2%!(&6("HQ'U!^WC^QE\9?VB
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M>6%!.'.U43D*<G@97;OYP&')&<5^-O\`P5(_;W\(_"3X7^*?@+\-/$-EXN^.
M_P`5+"Z\&V^@^&[F'5+OPCI>O%M.O[[68K`W,D&J75A<36/A_2%:VU6ZO[B.
M\5!:VS%OD\NPF)QV/P\,+&3MC*5652*;C3I0G"4JCDDURJ*:;\[ON?U!X@<3
M9/PEP;G&8Y[B:$(4\FKX2GA7**Q>8XC$X"K0I8+!4N:,J]3$59QI>SA&3DWR
MV;/&/^"`.NZI=_`+XT:#+Y@T71_BQ8W^ER2[VB2YU?PAHXU6TCSP`L>EV5S+
M&I&V>^E=@6E!/]`BAG)#$$#'8]0/J>.>GN>W%?G-_P`$N_V7M5_9>_95\/>&
M/%=F;7QUXVU6]^(/C?3V.Y],UC7++3K.RT:5Q@//I.@:9I%C?[%2)=2BOA$F
MPAG_`$<B5@26&.3_`$Q_GUK7/<53KYKC*M%J<9UVE427O6Y8-W2L]8OY'C^!
M^39ED'A9P5EF:T*F&QU/**=6MAZR2KX6&(<L31P]2R7).E3KPA*.CBXN+2::
M2^6W<C]1_C14M%>3=^7W+_(_65[J26MN_O/YMW855F(#''4`[O\`=V@].I/?
M_$\5:I,#T'/!X'(]*EJ^CVTNN]G?\TB9*Z5G9IQ::W5FF_O5U\[GX-?![_@D
MKXP^%_\`P5B^*'_!1ZX^,WAO6?#'C^^\>7%O\,K?PCJEMK6G-XN\.:;X?B6?
MQ))K$MC<+97&GR3NT6E*)TD1%,;!C7[KE_W6["@A5Y_ARPYP3C`ZX)([%L#-
M7#'&>J(>_*J>0<@\CL0#]12E5(P54CT(&/RQ77CL;BLQG2GBZKJ2H86&$HNV
ML:5.5Z:U_ECH>;EN3X+*HUZ>#A*%/%8ZOC\0I2YI3K5[N3YK+[3NG;HEYGX,
M_M3?\$D?&G[1/_!3OX%?M_:;\9/#7AG0/@W_`,*D6_\`AO?>%-4U#6=;7X;>
M(]:\03M;:[!JUM::>=5AUA(;=)=-NC;R1?,9%8,/WB.1&H.`<D=<@-AOH2,\
M<8/.:D$:#HB#Z*!WSZ>O/UYIV!C&!CT[?E3Q6.Q.,C@Z=>?-3P%'ZMA8?\^Z
M"?/R?^!N4NNY6`RG!Y;5QU;"P<*F8XCZUBY-W]I7Y>3GVT;BDK:[+T/PN^(W
M_!*'QGXP_P""N_P^_P""D\/Q?\-67A?P;'HD4_PMG\+ZD^N7O]E_#C6_`C&/
MQ*FK"QA+S:O#J)W:3(B11O#O+D-7W)^W7^P-\!OV_O@Y=?"7XW:1,3:W$FI>
M!_'.BI:VOC#X?>(S:M:KK7A_4YK:Y$<5Q$$@U?29XFTK6+6.."]A5X;.ZL_N
MORT_N)V_A';..W;)QZ9/J:4JIX*@CT(%;U,WS&I6P.)6)G2Q&74*6&PE6D^6
M5.A0BHP@]'=<MXRUU3:.:GP_E<*694*F%A7P^:XEXS%TJOO1GB)*\Y]+7FE*
M-MFNY_&]9?\`!`__`(*E?!I+KX>_LQ?\%0=9\*?!&:><6^B#XE_'?X8W.G6D
M]RV3!X2\$3Z_X9%^]N(TO+NQU/2GOW5EF=8FPOZ1?\$VO^"$WPH_8R^(;?M%
M?&+XB:G^TG^TUF[N=,\<Z_I\EKX<\(ZEJ<+07^N>'M,UB^UW6=0\5SV\EU8R
M>+=?U:XOH[6YN(]-L],EEFN9_P!_MB?W5X)(^4<$\D].I/)/>EVK_='/7@5Z
M6-XMSS,,/4P^(KX>G"O9XCZMA,/AY8BT5"U6I3IQFXM*\HIV<M;'EX'@?(,O
MQE+&TJ.)J5L/)SPL<1BJU>AA)-W3P^'G)TH-/5-IM:+S/P;_`."@'_!)+Q=^
MV/\`MS_LO_M;Z#\9O#G@C1OV?)OAFVI^"M3\(ZEK6I>(E\"?$^3Q]<_8M5M-
M9TZTL&O;24V$0FM;@Q39E9&0%3^[%OF6(,PVL,`CMN*+N`)`..>"0,\5;*(>
MJJ?JH]_;W/YFE`"]`!]`!V`[>P`^@`[5Y&+S'%X["X/"8F494LOH_5L(HJWL
MJ'-SJFM%>TVW?\CW,#E.#R_%9AC,-&4:V9XB.*Q;;NJF(45"4VNTH146O+[O
MYWO^"D7_``0?\._M8_&4?M3_`+./QFU#]FO]I&>73KO6]<LH-13PYXBUO2+=
MH+#Q7%>^'+S3/$GA+Q?#:Q6MO/KNBW5Y:W$5A;3S:,U\;R\O?E#0_P#@A7_P
M4%^.UQI7A?\`;U_X*:_$#XB_!73;N%]2^&W@CQI\2O$[^*K:UN`PCU"]\?)I
M>AZ?J31*$&J:GX8\7:C9R37.V:Z/[Z7^M#:I&"`1Z8&/RZ4A5<'Y5QUQ@8R.
MG'M7JT.*\\P^&HX2&)ISHT(<E&=?#4*^)H1TTH5ZE.4Z:TV322T5CPL3P+P]
MBL95QD\-6ISQ$^;$4L/BJ]##XEW6M:A3FH3EOJUJ]7J?S^_\$QO^"-M__P`$
MY?VH_CW\;[#XLZ!XL^'WQ.\.^)O!O@3X?Z=X>UO3]7\$^&[_`.(.D>*?#%EJ
M6N:KK6KOKDFD:+I%MH5U<+&DT\X%](Y7S,_SX?L4?L)_!?\`X*$?\%*_^"GO
MP3^,W]KV-I9S_&OQ1X,\7>'KB*#Q!X,\7Q?M!Z-IMEKUD+A)K/48DL]1O=/O
MM(OXY;'4M+N[BUD6.YCT^^L?]`:XA\Y,(B')^=3M`;H0Q)1MV-@3!_A8]PN/
MS$_9+_X)7?!#]D']J7XX?M6_#_Q9\2-8\=?'V'Q7!XNT?Q3JNB7?A?3X_%WC
M>Q\>ZA_8EEI^AV%[`]OK%C#!8R76H7;+8S7<<P9_(<>A@N,,32AGF)S',*SS
M;,L+A:&%Q48J,O:8:M!QC>/14(N$G)2BUHU9V/&S'@;"2K\/X/+L%'^R<#C\
M5B,?AYUI<LZ>(HN*;YI.3M)I+E:DK733M?\`!K5O^#?3_@I=::>_PA\)_P#!
M3S7)OV<W$MBWA35/&OQVTJQCT*:57^Q7/PIL?$.I>!K[]RTL=U"NNV]M>/\`
M,T4"WDJ6O[9?\$R?^"1?P#_X)N:)JFH^&;Z]^)7QK\8:=%8>+OC!XEL+*TU%
MM,@E2=_#O@W2X$F7PQX=DNH[:XU&U%_J.IZU-9V$FMZC=P:=I5KI_P"O"JO.
M%'7DX&21CD_D/R%*%4=%4<`<`#A1A1TZ`<#T'`KSL?Q7GF987ZKB,33C1E%.
M4:&&HX7VDN5+FK>PA3]JY+5\[=WJ[GN9?P5P_EN)6,PF'KNJG>F\3BJV*5)7
MORT57<O96>SA:VEK'Q=^VQ^PE\!OV]O@O?\`P9^.^C75WIBS_P!K>%?%.AM9
MV?B_P%XGBM;JUM_$?A34KVSU""VO3;W5Q:WEG?VM]I>J6-Q<V6H6=Q#,/+_F
MOT__`(($_P#!3_X)+>^`?V5/^"G>K>$/@Q?2S^3H?_"P?CK\*[FRMY6!F:#P
MIX&N/$?A_P"WC+B74;#4=*N+M%BA9XE#.?[(L#D8&#U&.OUHVKQ\J\=.!Q]/
M2LLKXBS;)\,\'A*].>&<U-4,5AZ.*I0E>[G3C6A+V<^THVU2O>RMKG'"&2YY
M7^LXRC5IXEPY)8G!XBM@\1**Y>6,ZE&:<X65FI7?9J[/YZ?^"<__``0A^&/[
M(OQ1@_:/^/?Q-U7]IS]I.UOKG4=(\4>(;6=/"GA75;J$V]WXAT^PUR^UO7?$
M'BN1)ITB\4>(-4DFLY'AN-.TK3[RW@O$^O/^"H/_``2U^$'_``4L^''A_0O%
MFKWG@/XI>`WU"Y^'/Q3TFQMM0O-(75C;?VAH'B#2YFB.N>$]4-K%)=V4=Y97
M5G>)%>65[%'+J5GJ7ZL[$'1%Y.3\HY/KTZ^]!1#C**<=,J#CZ<<5E5S[.*V9
M4\VJ8V=3&T)0]A5<84U1IQ7+[.-.DHP<?9^XDXM-7YDTVC;#<+9'A<JJ9-3P
M%-8"NE+$4Y5*M2=7$)QY<3[6I*4XUHJ*<9)W4DGLK/\`C&\)?\&]/_!1N#2E
M^#7BK_@I;J>D_LU;X[2[\%^%_&GQPU/3+K16\E;BUC^%NIZWH?@;3%F@B!DA
M;6=0M4,TSF&[;Y9_L+]G3_@WTTK]EO\`;Z^#W[4WP@^,UC'\(/A+%HXM/AMX
MC\/ZIJ?C;6K^/X83>"_$NN:IXOCU2WT=+_Q-XKO;_P`6F"Q\/6NGVD&H-86M
MK&ELDDG].X1`<A%!ZY"C.3P3T[BC8G/R+SR?E')R3D\>I)^I->C6XRX@KT:F
M&GBJ*PU6C7I5*%+"4*$*SKRYG*O*E",ZC6R<FWU35SR<-X>\.86>&J0I8JM5
MPM>E6H5\5BZV(K453NU3H\\G""N]&H72=M;(_/S_`(**_L$_#G_@HA^SKJ?P
M*\?ZS?>$[JSUNQ\8>`O'&EVUO?WW@[QEI=IJ%C9ZFVFW+)#JFG7-CJNIZ7JV
MFM-9R7>FW]PMK>V%XEM>P_@C^SC_`,$`/VY?A9\1OA;9>+O^"AEW<?L\_"SX
MB^#_`!K;?#'PGK'Q972==M?"OB>R\1+I`\!W^O:=X.\/)J$MH(A,MSKJ6K2W
M,@M;K?F7^O':O/RKSUX'.>N>*-B9!VKD`@':,@'&0#CH=JY^@]!7#E_$6<9=
M@*N68?%IX"K*I4^JUJ%"O"E5K*/MI49U82J4XU&MHR5K)IZV/2S#A+)<RS"C
MFM?#2IX^C[*/ML/7K4?:PH*U%5HPFO:NFKI<]T[ZKJ?C'_P6)_X)B>*O^"FG
MPU^#/@3PM\6/#_PIN/AEXUU[Q7>:EKWA?4?$L&K1:MX>CT5;.W@T_5=+DMI(
M9`;HR2RS)(@\L+&,S+]YWG[,/PY\;?LOZ%^S)\:=$TCXE^!4^%OA7X;^*=-U
M&S>*PUS^P="T[2?[4LHVE-YI5W'=V<>IZ-=6EQ'J>EWT5K<P7GVNWAEC^JB`
M>H!^H'^>PHVJ1@JN,8Q@8QZ8]*XJF9YC5P>!P4ZZ=#+<14Q6`IQ4J:PV(K3<
MZM6,X-3E*3E)I2=E)]K)=T,BRZ..QN/="-2MF>'HX3'\Z4HUJ&'IPIT8<K5O
M=4%?F33WWU/X\O&G_!N)^U#\$O&WB#Q%_P`$[?V]/%'P9\.Z\\RS:'XB\9?$
M7X;^)K2RED:5;"[\<_"".<^)H+4*L$#7OA?3YA;01(\K>6V_W#]E#_@W-@MO
MB_IWQZ_X*%?M#ZQ^UCXXTJZL]3A\(RWGB;5_#&JZE9,)+?\`X3GQ7XYOKWQ1
MXXTR*0R3+HK6&@Z?/'(EIJ2ZC9?;8=2_J;$<:X"HB@8P`JC&!@8P.PX'H..E
M."J.`J@<\``=3D_F>3[U[E3C3B&IA981XNE"G.G&G*K#"8>.+G"*LX5,4H*M
M*,EO[U]7KU/"I\`<-T\5#%_5:TYTZOMJ5&IBL1+!TYZ>]'"<_L>967*^5)=C
M\3/^"E7_``14^!?_``4)U;0?B.?&_C+X._'+PAX;TSPEX7\<>'KD:KX<3PYH
MMQ=W>C^']4\&7<]M!!IFG7%]J$UD_A:_\/7D,U[=O/+="=U/Y1WW_!!;_@J7
MK>CR_"#Q7_P56\3:O\!KR/\`LZ^T*]\;_'768Y]#41P)8S_#[4?$;:!=6/EN
M5719O$KZ()O*DDM'$0!_L.V)G.U<Y!SM&<CH>G4=O2EVK_='Y"L,%Q7GV`P]
M/"T,72E0I1G[*-?"86N\.YRC)>PE4I2E!1L^5M\RNG=.]^C,.".'\RQ4L;B,
M-7AB*EU6EA\9B:$,0FTVJT*<XQDI/XHI*+3LDD?GY_P3V_X)\_!__@G5\"(?
M@[\*;O5->NM4U9_$_CSQSKRVD6M>-O$TT,-LU[<Q6,*V]AI5A;1)8Z!I,(F_
ML[3XXUN;W4=1GU/5M2X3]GS]A[Q#\%?VTOVAOVHK[Q_I&OZ1\:K+Q!:V/A&U
MT2]L=1T+^V?%'AO7TEN=1EOKF"_$$6B7$+B.UM=TDL#`D%POZ>[5QMVKM`P!
M@8`QC&,8QCC'I2&*(D$QQDCH2BDCIT...@_(>E>5+,L=.>.J3KRJU<PCR8FK
M4UE5CH_?Z736BC:,4DDNSS#@KA[,L1POB,1@E&?!V/EFF01HU)THX3&SPU3"
M2G)1?[V#HUJRDIW;E.[81XV)M.1L7!'((P,$'GJ/>H)A\^<,>,9!P.0>O!X]
M_P#)M4F!Z#\JX;>ZX]X\M_NUMUVV/J^6+23BFE;1W5K:IJSZ-+KL?B;^V)_P
M3+^+G[0O[3L?[1_PM_:*3X+Z[8^$=&\/:1=Z5I?B&'Q5I,]C;:S8W][IGB70
M/$NAWED-1L-8GL)C;")Y+"XO;21_+N&KR)/^"8G_``4#!"M_P4Y^*N\?)O/B
MOXQ[SZ;L?$OEF^\26RS'<QW$FOZ#MB?W%_[Y'O[>Y_,^M&Q.FU<'J-HY_2O=
MH\19E2I4Z+>&J0H0A3H^TPU*I*,(I+E<IQDVM-MMC\7S'P$X!S+,LQS:4.(,
M'C<UQ\LTQ_\`9?%&?Y7A\5CZB49UZN&P&/H4&W#W5)4U-Z.4FT?SY3?\$J?V
MV==4Z9XW_P""E7Q:U/P[=#9J-C_:_P`4]2%W`3MDA:'4OB@]EM*,P(GMYT8X
M!3`.?LC]E'_@E9^SI^S#KEO\09GUGXL_%&(F[A\;?$&/3[PZ7?2JR37V@:(E
MF;73;UQ)(/[3O)M4UR%9IXX=6B@GD@K]1=B'&57C@?*.!QP./8?D*"JD8*J1
MC'('3T^GM66+SS,L73]DZT</3EI/ZK2I4)-=5%P@FKK1IMJW2^IUY%X&^'60
M8^AFU')JF9YG@ZCKX+%\09EFN>U<)75O9U*4LTQN*C^[:O%^S4XNSC)-%:T&
M$D`!P)"`<``@*O*G<V1[EB3W)/-6Z1551A0%'H``/TI:\EN[;_R^_32[W?F?
;KD4U%)[I*_O2GKUM*?O-7VOLM-D%%%%(H__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
